$4.94
1.59% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

MannKind Corporation Stock News

Neutral
GlobeNewsWire
24 days ago
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Positive
Seeking Alpha
about one month ago
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential expansion into IPF and MannKind's in-house developments in NTM-LD and IPF present significant growth opportunities despite competitive threats. MannKind's financial health is solid, with strong liq...
Neutral
Seeking Alpha
about one month ago
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & ...
Neutral
GlobeNewsWire
about one month ago
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v.
Neutral
GlobeNewsWire
about one month ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Neutral
Seeking Alpha
about 2 months ago
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 8 includes American Superconductor, Skye Bioscience, Healwell AI, Dell Technologies, MicroStrategy and MannKind, among others.
Neutral
GlobeNewsWire
3 months ago
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effecti...
Neutral
Seeking Alpha
4 months ago
MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, wit...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today